CLN-978 is under clinical development by Cullinan Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CLN-978’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLN-978 overview
CLN-978 is under development for the treatment of B-cell acute lymphocytic leukemia, B-cell non-Hodgkin lymphomas including diffuse large B-Cell Lymphoma, primary mediastinal b-cell lymphoma, follicular lymphoma, systemic lupus erythematosus, mantle cell lymphoma, nodal marginal zone b-cell lymphoma and extranodal marginal zone b-cell lymphoma. It is a tri-specific monoclonal antibody that acts by targeting CD3 and CD19. It is administered through subcutaneous route.
Cullinan Therapeutics overview
Cullinan Therapeutics, formerly Cullinan Oncology Inc, is clinical-stage biotechnology company. It focuses on the discovery and development of oncology therapies. Its product pipeline includes CLN-081 for the treatment of non-small cell lung cancer; CLN-619 against pan-cancer; and CLN-049 to treat relapsed and refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Cullinan Therapeutic;s pipeline also includes drug programs such as CLN-418 for multiple solid tumors; CLN-978 to treat B-cell non-Hodgkin lymphomas and CLN-617 for treatment of pan-cancer. The company also provides various patient support programs. Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CLN-978’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
